As Madrigal faces MASH rivals, keeping patients is as critical as finding new ones

Madrigal’s drug Rezdiffra has exceeded expectations, and the company plans to stay ahead of incoming competition with a highly targeted patient approach.

By Kelly Bilodeau • Nov. 19, 2025

Is that pharma influencer human or AI?

Agentic AI is making its way into pharma marketing — and raising a slew of potential challenges around regulations and ethics.

By Meagan Parrish • Nov. 14, 2025

Drugs are winning approval even when trials fail — but should they?

About 10% of FDA-approved drugs in recent years have won clearance despite a trial failure, raising safety and ethical concerns.

By Kelly Bilodeau • Nov. 12, 2025

After a lackluster first drug launch, a new CEO is finding Geron’s commercial footing

Harout Semerjian, whose pedigree includes launching the Novartis cancer blockbuster Gleevec, is aiming to boost awareness about Geron’s Rytelo to give it momentum.

By Alexandra Pecci • Nov. 12, 2025

Alzheimer’s drug uptake hits its stride after a sluggish start

Sales of Eli Lilly’s Kisunla, and Eisai and Biogen’s Leqembi are on the rise as doctors grow more confident and new dosing options ease treatment hurdles.

By Kelly Bilodeau • Nov. 10, 2025

Half of Merck’s sales are in jeopardy. Can Keytruda’s sequel save the day?

This week’s launch of subcutaneously administered Keytruda Qlex gives Merck a safety net for the cancer drug’s daunting patent cliff.

By Michael Gibney • Oct. 2, 2025

Is pharma’s IRA pricing battle running out of steam?

Despite recent court losses, the legal tides could still turn in the industry’s favor.

By Meagan Parrish • Sept. 26, 2025

A brewing GLP-1 showdown, from Big Pharma pills to a biotech implant

Newcomers looking for a way into the obesity space are developing unique methods to snag market share.

By Amy Baxter • Aug. 27, 2025

The biggest Big Pharma losers in the first half of 2025

What goes up must come down — here are the major drugs falling the hardest at the top companies so far this year.

By Michael Gibney • Aug. 21, 2025

MAHA leaders may take aim at pharma DTC advertising

RFK Jr. has his sights set on increasing advertising enforcement against pharmas, but may not come down as hard on the industry as previously thought.

By Amy Baxter • Aug. 20, 2025

Despite FDA ruling, compounded GLP-1s are still giving Novo and Lilly headaches on the market

Copycat weight loss drugs were supposed to be pulled from the market, but pharmacies have found a loophole. 

By Amy Baxter • Aug. 18, 2025

3 ways the GLP-1 market has changed shape this year

Novo Nordisk and Eli Lilly’s quarterly earnings revealed shifting dynamics in the lucrative obesity space.

By Amy Baxter • Aug. 12, 2025

As gene therapies falter on the market, this biopharma is aiming to defy the odds

After a strong launch for its cancer gene therapy, Ferring Pharmaceuticals is setting the stage for long-term growth.

By Meagan Parrish • Aug. 8, 2025

Roche pushes ahead with late-comer strategy in obesity

The Swiss pharma company announced several updates to its obesity portfolio in its latest earnings report.

By Amy Baxter • July 30, 2025

Novartis’ Zolgensma sales fall again as gene therapy market woes persist

Novartis has seen sales decline in a difficult gene therapy market. Is there hope on the horizon?

By Michael Gibney • July 22, 2025

3 major patent losses this year — and a key strategy to fill the gaps

Despite promising pipelines, most new launches are missing sales targets, forcing pharmas to rethink sales strategies.

By Kelly Bilodeau • July 21, 2025

Need a DTC platform? Here’s how one company built its own.

Currax Pharmaceuticals was ahead of the curve when it set up a direct access platform for its obesity med. 

By Amy Baxter • July 14, 2025

With Verona deal, Merck wagers on strength of lung drug’s patents

The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make good on the deal, other secondary patents will need to hold up.

By Jonathan Gardner • July 11, 2025

Trump says ‘very high’ pharmaceutical tariffs coming soon

While Trump indicated drug levies would be as high as 200%, he added that pharma firms would first be given time to bring manufacturing back to the U.S.

By Philip Neuffer • July 9, 2025

GLP-1 roadblocks: Discontinuation rates soar as insurers clamp down

As more drugmakers aim for the lucrative weight loss market, patient challenges linger.

By Amy Baxter • July 7, 2025

3 of the year’s most notable FDA nods

The agency has granted approvals steadily in the first part of the year, including nods for several breakthrough therapies.

By Meagan Parrish • June 27, 2025

Biogen scores Cannes Festival win with dark humored campaign

The company’s unique campaign for a rare, terminal illness nabbed millions of views and a spot on the main stage at the Cannes Lions Festival of Creativity.

By Alexandra Pecci • June 24, 2025

Megablockbusters are the holy grail. Here’s how drugmakers are getting there.

More drugs surpassed $10 billion in revenue last year than ever before.

By Amy Baxter • June 23, 2025

Is DTC pharma advertising coming to an end?

A bill introduced in Congress fulfills a Trump administration goal of ending direct pharma ads to patients.

By Amy Baxter • June 18, 2025

The MAHA agenda won’t include expanding GLP-1 coverage — for now

Despite axing a Biden-era proposal for government coverage of obesity drugs, health officials have signaled a potential path forward.

By Amy Baxter • June 2, 2025